Latest Trials Latest NewsFAQ

PFIZER INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1849-01-01

Employees: 88K

Market Cap: $163.3B

Website: http://www.pfizer.com

Clinical Trials

Sunitinib Malate Schedule 4/2 vs. Sunitinib Malate Continuous Dosing As First-Line Therapy For Metastatic Renal Cell Cancer (RCC)

Phase 2

Completed

Conditions: Carcinoma, Renal Cell

Interventions: Drug: Sunitinib Malate Continuous Daily Dosing
Drug: Sunitinib Malate Schedule 4/2

First Posted Date: 2005-12-21

Last Posted Date: 2011-09-05

Lead Sponsor: Pfizer

Target Recruit Count: 317

Registration Number: NCT00267748

Locations: 🇺🇸
Pfizer Investigational Site, Madison, Wisconsin, United States

A Clinical Trial Comparing Torcetrapib/Atorvastatin To Simvastatin In Subjects With High Cholesterol (A5091031).

Phase 3

Terminated

Conditions: Hyperlipidemia
Dyslipidemia
Hypercholesterolemia

First Posted Date: 2005-12-20

Last Posted Date: 2012-02-17

Lead Sponsor: Pfizer

Target Recruit Count: 640

Registration Number: NCT00267280

Locations: 🇺🇸
Pfizer Investigational Site, Tacoma, Washington, United States

A Clinical Trial Comparing Torcetrapib/Atorvastatin to Ezetimibe/Simvastatin In Subjects With A Cholesterol Disorder.

Phase 3

Terminated

Conditions: Hyperlipidemia
Dyslipidemia

First Posted Date: 2005-12-20

Last Posted Date: 2007-12-10

Lead Sponsor: Pfizer

Target Recruit Count: 1784

Registration Number: NCT00267267

Locations: 🇺🇸
Pfizer Investigational Site, Spokane, Washington, United States

A Clinical Trial Comparing Torcetrapib/Atorvastatin To Simvastatin In Subjects With High Cholesterol.

Phase 3

Completed

Conditions: Hyperlipidemia
Dyslipidemia
Hypercholesterolemia

First Posted Date: 2005-12-20

Last Posted Date: 2007-11-21

Lead Sponsor: Pfizer

Target Recruit Count: 640

Registration Number: NCT00267254

Locations: 🇺🇸
Pfizer Investigational Site, Milwaukee, Wisconsin, United States

A Study In Patients With Non-Small Cell Lung Cancer Testing If Erlotinib Plus SU011248 (Sunitinib) Is Better Than Erlotinib Alone

Phase 2

Completed

Conditions: Carcinoma, Non-Small-Cell Lung

Interventions: Drug: erlotinib
Drug: placebo
Drug: sunitinib

First Posted Date: 2005-12-14

Last Posted Date: 2013-02-06

Lead Sponsor: Pfizer

Target Recruit Count: 162

Registration Number: NCT00265317

Locations: 🇪🇸
Pfizer Investigational Site, Santander, Cantabria, Spain

Phase 2 Study of the Safety and Efficacy of UK-500,001 in Adult Patients With COPD

Phase 2

Terminated

Conditions: Pulmonary Disease, Chronic Obstructive

First Posted Date: 2005-12-09

Last Posted Date: 2007-07-23

Lead Sponsor: Pfizer

Target Recruit Count: 324

Registration Number: NCT00263874

Locations: 🇬🇧
Pfizer Investigational Site, Manchester, United Kingdom

Extension Study Of Stage 1 Subjects Of Study A3921009 For The Prevention Of Acute Rejection In Kidney Transplant Patient

Phase 2

Completed

Conditions: Kidney Transplantation

Interventions: Drug: CP-690,550
Drug: Tacrolimus

First Posted Date: 2005-12-08

Last Posted Date: 2015-07-13

Lead Sponsor: Pfizer

Target Recruit Count: 46

Registration Number: NCT00263328

Locations: 🇺🇸
Annette C & Harold C Simmons Transplant Institute, Dallas, Texas, United States
🇺🇸
Transplant Research Institute, Los Angeles, California, United States
🇺🇸
Balboa Institute of Transplantation, San Diego, California, United States

and more 24 locations

Study Evaluating SKI-606 (Bosutinib) In Philadelphia Chromosome Positive Leukemias

Phase 2

Completed

Conditions: Chronic Myeloid Leukemia

Interventions: Drug: Bosutinib

First Posted Date: 2005-12-05

Last Posted Date: 2017-07-27

Lead Sponsor: Pfizer

Target Recruit Count: 571

Registration Number: NCT00261846

Locations: 🇺🇸
The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
🇨🇦
University Health Network Princess Margaret Hospital, Toronto, Ontario, Canada
🇺🇸
Penn State Milton S Hershey Medical Center, Hershey, Pennsylvania, United States

and more 107 locations

Evaluation Of Linezolid Pk Profile In Burns Patients

Phase 1

Completed

Conditions: Burns

First Posted Date: 2005-11-21

Last Posted Date: 2009-07-14

Lead Sponsor: Pfizer

Target Recruit Count: 16

Registration Number: NCT00255996

Locations: 🇫🇷
Pfizer Investigational Site, Paris, France

Trial of Paclitaxel/Carboplatin + PF-3512676 vs Paclitaxel/Carboplatin Alone in Patients With Advanced Non-Small Cell Lung Cancer

Phase 3

Terminated

Conditions: Carcinoma, Non-Small-Cell Lung

Interventions: Drug: Paclitaxel + Carboplatin
Drug: PF-3512676 + Paclitaxel + Carboplatin

First Posted Date: 2005-11-17

Last Posted Date: 2015-03-30

Lead Sponsor: Pfizer

Target Recruit Count: 828

Registration Number: NCT00254891

Locations: 🇬🇧
Pfizer Investigational Site, Swansea, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy